Discovery of New Differentiation Agents for Neuroblastoma Therapy
Neuroblastoma is one of the most common and lethal types of childhood cancers. Although differentiation therapy is the main therapeutic approach for treating neuroblastoma, many high-risk neuroblastoma cases have been found to be resistant currently available differentiation agents. The goal of this project is to identify new differentiation-inducing candidates that have the potential to be developed as clinically applicable anti-cancer drugs for treating neuroblastoma. The potential of the identified compounds as anti-cancer drugs will be investigated by combined chemistry, biochemistry and cell biology approaches as well as animal studies. It is expected that this project and the future follow-up studies will eventually lead to new differentiation therapies for neuroblastoma resistant to currently available therapeutic approaches.
By Dr. Liqin Du